Clinical Evaluation of Patients With X-linked Retinoschisis

Key facts

Sponsor

Beacon Therapeutics

Principal Investigator

Matt Feinsod, MD, md

Applied Genetics Technologies Corporation

Intervention

Dorzolamide 2% TID or brinzolamide 1% TID(drug)

Enrollment

66 target

Eligibility

7 years · MALE

Timeline

2012 – 2016

Study locations (3)

• University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States
• Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States
• Retina Foundation of the Southwest, Dallas, Texas, United States

Collaborators

Foundation Fighting Blindness

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for X-linked retinoschisis

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGEARLY PHASE1NCT06289452
  Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
  InnoVec Biotherapeutics Inc.
• RECRUITINGEARLY PHASE1NCT06345898
  Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)
  West China Hospital
• RECRUITINGPHASE1, PHASE2NCT05878860
  ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
  Atsena Therapeutics Inc.
• RECRUITINGNANCT05814952
  Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

See all trials for X-linked retinoschisis →